UPADACITINIB

Brand name:

• Rinvoq®

Pharmaceutical company:

Abbvie Pty Ltd

Condition/indication:
(therapeutic use)

• Crohn disease

PBAC Submission type:

Change to PBS listing (–)

Comment:

To be considered at a future PBAC meeting

Related medicines:

• UPADACITINIB

Submission received for:

March 2023 PBAC meeting

Opportunity for consumer comment:

Open 23/11/2022 and close 25/01/2023 (see PBS Website)

PBAC meeting:

Held on 08/03/2023

PBAC outcome published:

Not Applicable (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---